The association between cigarette smoking and inflammation: The Genetic Epidemiology Network of Arteriopathy (GENOA) study

Martin Tibuakuu, Daisuke Kamimura, Sina Kianoush, Andrew P. DeFilippis, Mahmoud Al Rifai, Lindsay M. Reynolds, Wendy B. White, Kenneth R. Butler, Thomas H. Mosley, Stephen T Turner, Iftikhar Jan Kullo, Michael E. Hall, Michael J. Blaha

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

To inform the study and regulation of emerging tobacco products, we sought to identify sensitive biomarkers of tobacco-induced subclinical cardiovascular damage by testing the cross-sectional associations of smoking with 17 biomarkers of inflammation in 2,702 GENOA study participants belonging to sibships ascertained on the basis of hypertension. Cigarette smoking was assessed by status, intensity (number of cigarettes per day), burden (pack-years of smoking), and time since quitting. We modeled biomarkers as geometric mean (GM) ratios using generalized estimating equations (GEE). The mean age of participants was 61 ±10 years; 64.5% were women and 54.4% African American. The prevalence of smoking was 12.2%. After adjusting for potential confounders, 6 of 17 biomarkers were significantly higher among current smokers at a Bonferroni adjusted p-value threshold (p<0.003). High sensitivity C-reactive protein was the most elevated biomarker among current smokers when compared to never smokers [GM ratio = 1.39 (95% CI: 1.23, 1.57); p <0.001]. Among former smokers, each pack-year of cigarettes smoked was associated with a 0.4% higher serum level of hsCRP [GM ratio = 1.004 (95% CI: 1.001, 1.006); p = 0.002] and each 5-year lapsed since quitting was associated with a 4% lower serum level of hsCRP [GM ratio = 0.96 (95% CI: 0.93, 0.99); p = 0.006]. However, we found no significant association of smoking intensity or burden with biomarkers of inflammation among current smokers. HsCRP appears to be the most sensitive biomarker of inflammation associated with cigarette smoking of those investigated, and could be a useful biomarker of smoking-related injury for the study and regulation of emerging tobacco products.

Original languageEnglish (US)
Article numbere0184914
JournalPLoS One
Volume12
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Molecular Epidemiology
smoking (habit)
Biomarkers
Tobacco Products
epidemiology
biomarkers
inflammation
Smoking
Association reactions
Inflammation
tobacco
cigarettes
Tobacco
C-reactive protein
African Americans
Serum
C-Reactive Protein
hypertension
Hypertension
Wounds and Injuries

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Tibuakuu, M., Kamimura, D., Kianoush, S., DeFilippis, A. P., Al Rifai, M., Reynolds, L. M., ... Blaha, M. J. (2017). The association between cigarette smoking and inflammation: The Genetic Epidemiology Network of Arteriopathy (GENOA) study. PLoS One, 12(9), [e0184914]. https://doi.org/10.1371/journal.pone.0184914

The association between cigarette smoking and inflammation : The Genetic Epidemiology Network of Arteriopathy (GENOA) study. / Tibuakuu, Martin; Kamimura, Daisuke; Kianoush, Sina; DeFilippis, Andrew P.; Al Rifai, Mahmoud; Reynolds, Lindsay M.; White, Wendy B.; Butler, Kenneth R.; Mosley, Thomas H.; Turner, Stephen T; Kullo, Iftikhar Jan; Hall, Michael E.; Blaha, Michael J.

In: PLoS One, Vol. 12, No. 9, e0184914, 01.09.2017.

Research output: Contribution to journalArticle

Tibuakuu, M, Kamimura, D, Kianoush, S, DeFilippis, AP, Al Rifai, M, Reynolds, LM, White, WB, Butler, KR, Mosley, TH, Turner, ST, Kullo, IJ, Hall, ME & Blaha, MJ 2017, 'The association between cigarette smoking and inflammation: The Genetic Epidemiology Network of Arteriopathy (GENOA) study', PLoS One, vol. 12, no. 9, e0184914. https://doi.org/10.1371/journal.pone.0184914
Tibuakuu, Martin ; Kamimura, Daisuke ; Kianoush, Sina ; DeFilippis, Andrew P. ; Al Rifai, Mahmoud ; Reynolds, Lindsay M. ; White, Wendy B. ; Butler, Kenneth R. ; Mosley, Thomas H. ; Turner, Stephen T ; Kullo, Iftikhar Jan ; Hall, Michael E. ; Blaha, Michael J. / The association between cigarette smoking and inflammation : The Genetic Epidemiology Network of Arteriopathy (GENOA) study. In: PLoS One. 2017 ; Vol. 12, No. 9.
@article{4ec5b69029df459b90687d88925aa73b,
title = "The association between cigarette smoking and inflammation: The Genetic Epidemiology Network of Arteriopathy (GENOA) study",
abstract = "To inform the study and regulation of emerging tobacco products, we sought to identify sensitive biomarkers of tobacco-induced subclinical cardiovascular damage by testing the cross-sectional associations of smoking with 17 biomarkers of inflammation in 2,702 GENOA study participants belonging to sibships ascertained on the basis of hypertension. Cigarette smoking was assessed by status, intensity (number of cigarettes per day), burden (pack-years of smoking), and time since quitting. We modeled biomarkers as geometric mean (GM) ratios using generalized estimating equations (GEE). The mean age of participants was 61 ±10 years; 64.5{\%} were women and 54.4{\%} African American. The prevalence of smoking was 12.2{\%}. After adjusting for potential confounders, 6 of 17 biomarkers were significantly higher among current smokers at a Bonferroni adjusted p-value threshold (p<0.003). High sensitivity C-reactive protein was the most elevated biomarker among current smokers when compared to never smokers [GM ratio = 1.39 (95{\%} CI: 1.23, 1.57); p <0.001]. Among former smokers, each pack-year of cigarettes smoked was associated with a 0.4{\%} higher serum level of hsCRP [GM ratio = 1.004 (95{\%} CI: 1.001, 1.006); p = 0.002] and each 5-year lapsed since quitting was associated with a 4{\%} lower serum level of hsCRP [GM ratio = 0.96 (95{\%} CI: 0.93, 0.99); p = 0.006]. However, we found no significant association of smoking intensity or burden with biomarkers of inflammation among current smokers. HsCRP appears to be the most sensitive biomarker of inflammation associated with cigarette smoking of those investigated, and could be a useful biomarker of smoking-related injury for the study and regulation of emerging tobacco products.",
author = "Martin Tibuakuu and Daisuke Kamimura and Sina Kianoush and DeFilippis, {Andrew P.} and {Al Rifai}, Mahmoud and Reynolds, {Lindsay M.} and White, {Wendy B.} and Butler, {Kenneth R.} and Mosley, {Thomas H.} and Turner, {Stephen T} and Kullo, {Iftikhar Jan} and Hall, {Michael E.} and Blaha, {Michael J.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1371/journal.pone.0184914",
language = "English (US)",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - The association between cigarette smoking and inflammation

T2 - The Genetic Epidemiology Network of Arteriopathy (GENOA) study

AU - Tibuakuu, Martin

AU - Kamimura, Daisuke

AU - Kianoush, Sina

AU - DeFilippis, Andrew P.

AU - Al Rifai, Mahmoud

AU - Reynolds, Lindsay M.

AU - White, Wendy B.

AU - Butler, Kenneth R.

AU - Mosley, Thomas H.

AU - Turner, Stephen T

AU - Kullo, Iftikhar Jan

AU - Hall, Michael E.

AU - Blaha, Michael J.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - To inform the study and regulation of emerging tobacco products, we sought to identify sensitive biomarkers of tobacco-induced subclinical cardiovascular damage by testing the cross-sectional associations of smoking with 17 biomarkers of inflammation in 2,702 GENOA study participants belonging to sibships ascertained on the basis of hypertension. Cigarette smoking was assessed by status, intensity (number of cigarettes per day), burden (pack-years of smoking), and time since quitting. We modeled biomarkers as geometric mean (GM) ratios using generalized estimating equations (GEE). The mean age of participants was 61 ±10 years; 64.5% were women and 54.4% African American. The prevalence of smoking was 12.2%. After adjusting for potential confounders, 6 of 17 biomarkers were significantly higher among current smokers at a Bonferroni adjusted p-value threshold (p<0.003). High sensitivity C-reactive protein was the most elevated biomarker among current smokers when compared to never smokers [GM ratio = 1.39 (95% CI: 1.23, 1.57); p <0.001]. Among former smokers, each pack-year of cigarettes smoked was associated with a 0.4% higher serum level of hsCRP [GM ratio = 1.004 (95% CI: 1.001, 1.006); p = 0.002] and each 5-year lapsed since quitting was associated with a 4% lower serum level of hsCRP [GM ratio = 0.96 (95% CI: 0.93, 0.99); p = 0.006]. However, we found no significant association of smoking intensity or burden with biomarkers of inflammation among current smokers. HsCRP appears to be the most sensitive biomarker of inflammation associated with cigarette smoking of those investigated, and could be a useful biomarker of smoking-related injury for the study and regulation of emerging tobacco products.

AB - To inform the study and regulation of emerging tobacco products, we sought to identify sensitive biomarkers of tobacco-induced subclinical cardiovascular damage by testing the cross-sectional associations of smoking with 17 biomarkers of inflammation in 2,702 GENOA study participants belonging to sibships ascertained on the basis of hypertension. Cigarette smoking was assessed by status, intensity (number of cigarettes per day), burden (pack-years of smoking), and time since quitting. We modeled biomarkers as geometric mean (GM) ratios using generalized estimating equations (GEE). The mean age of participants was 61 ±10 years; 64.5% were women and 54.4% African American. The prevalence of smoking was 12.2%. After adjusting for potential confounders, 6 of 17 biomarkers were significantly higher among current smokers at a Bonferroni adjusted p-value threshold (p<0.003). High sensitivity C-reactive protein was the most elevated biomarker among current smokers when compared to never smokers [GM ratio = 1.39 (95% CI: 1.23, 1.57); p <0.001]. Among former smokers, each pack-year of cigarettes smoked was associated with a 0.4% higher serum level of hsCRP [GM ratio = 1.004 (95% CI: 1.001, 1.006); p = 0.002] and each 5-year lapsed since quitting was associated with a 4% lower serum level of hsCRP [GM ratio = 0.96 (95% CI: 0.93, 0.99); p = 0.006]. However, we found no significant association of smoking intensity or burden with biomarkers of inflammation among current smokers. HsCRP appears to be the most sensitive biomarker of inflammation associated with cigarette smoking of those investigated, and could be a useful biomarker of smoking-related injury for the study and regulation of emerging tobacco products.

UR - http://www.scopus.com/inward/record.url?scp=85029548963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029548963&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0184914

DO - 10.1371/journal.pone.0184914

M3 - Article

C2 - 28922371

AN - SCOPUS:85029548963

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e0184914

ER -